Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3901)	3/6/1998 9:01:00 AM
From: Oliver & Co	Read Replies (1) \| Respond to of 6136

JT to sell anti-HIV drug in Japan from late March March 5, 1998 09:02 PM TOKYO, March 6 (Reuters) - Japan Tobacco Inc said on Friday that it would start selling its anti-HIV drug Viracept in Japan from late March. JT said in a statement that the drug would be priced at 188.7 yen per tablet. In May 1997, JT applied for government approval to import Viracept, which is already being marketed in the United States. JT, the nation's cigarette monopoly, said in January it had granted sales rights in Japan for Viracept to Swiss-based Hoffman-La Roche, a unit of Roche Holding AG . JT and Agouron Pharmaceuticals Inc AGPH jointly developed the anti-viral therapy for HIV, the virus that causes Acquired Immune Deficiency Syndrome (AIDS). Viracept is a protease inhibitor, a drug that blocks the reproductive cycle of the HIV virus, it said. JT said a Japanese unit of Roche Holding would sell the drug in most parts of Japan, although sales in eight prefectures near Tokyo and Osaka would be carried out by Yoshitomi Pharmaceutical Industries Ltd . A JT spokesman said the company did not have a sales forecast for the Japanese market. The company said in January that the drug's U.S. sales totalled $214 million in the March-December period of last year. ((Tokyo Equities Desk +81-3 3432 9404 tokyo.equities.newsroom@reuters.com)) REUTERS -------------------------------------------------------------------------------- Following are Reuters Alerts related to this article -------------------------------------------------------------------------------- ALERT JAPAN TOBACCO SAYS TO START SELLING HIV DRUG VIRACEPT IN JAPAN FROM LATE-MARCH REUTERS -------------------------------------------------------------------------------- Worried about security? Please read this. If you're not using Microsoft Internet Explorer, you're not seeing all that Microsoft Investor has to offer. Terms of Use and Privacy Policy. cÿ1998 Microsoft Corporation and/or its suppliers. All rights reserved. c 1998 Reuters. All Reuters articles are delayed at least 15 minutes.

To: Biomaven who wrote (3901)	3/6/1998 9:03:00 AM
From: Oliver & Co	Respond to of 6136

NASDAQ Investor Forum Exhibitor Profile for Agouron Pharmaceuticals, Inc. March 5, 1998 03:31 PM PHOENIX--(BUSINESS WIRE)--March 5, 1998--The following is a profile for Agouron Pharmaceuticals, Inc., who will be an exhibitor at the NASDAQ Investor Forum, March 7, 1998, at the Phoenix Civic Center Plaza. Company Name: Agouron Pharmaceuticals, Inc. Trading Symbol: AGPH Company Address: 10350 North Torrey Pinces Road City/State/Zip: La Jolla, CA 92037-1020 Investor Relations: Donna Nichols, Vice President, Head of Corporate Communications Investor Relations Phone: 800/501-AGPH Industry: Biotechnology Website: www.agouron.com Summary Presentation: INNOVATIVE PHAMACEUTICAL PRODUCTS FOR SERIOUS DISEASES INVESTMENT FEATURES Powerful technology that we created Agouron Pharmaceuticals, Inc. is a company with a vital mission: to provide innovative drug therapies for people with some of the most difficult diseases of our time. At the company's core is a dynamic technology that was forged by Agouron scientists. This approach -- protein structure-based drug design -- allows for the design of novel drugs that inactivate the proteins that play key roles in cancer, AIDS and other serious diseases. This technology has allowed the company's scientists to overcome problems in drug discovery and design that were insurmountable by conventional methods. A highly successful entry into an expanding market Agouron's first commercial product, an HIV protease inhibitor, was cleared by the FDA last year just 38 months after it was first synthesized -- the most rapid program of development and commercialization of a new drug ever to be carried out in the U.S. pharmaceutical industry. This drug is used to treat HIV infection in adults and children and is marketed in many countries worldwide. It continues to gain significant market share (30%), making it the second most widely used drug in this important class of drugs. And there appear to be significant growth opportunities ahead. Currently, there are an estimated 900,000 people living with HIV in the U.S. Of these, only 23% (209,000 patients) are receiving protease inhibitors. Prescription data reveal that the protease inhibitor market is already over $1 billion today, with the potential to expand by at least 50% by the end of 1998. Strong sales that have exceeded expectations In the quarter that ended December 31, 1997, Agouron realized total revenues of $104.7 million -- a figure driven by $91.8 million second-quarter fiscal year sales of the company's HIV protease inhibitor. First-year sales of the product are nearing $300 million, a new record in the biopharmaceutical industry. And sales are projected to achieve $350 million in the U.S. for fiscal 1998. This drug has already garnered the highest share of this $1 billion market, competing successfully with products from some of the pharmaceutical industry's largest corporations. A deep product pipeline Currently, Agouron has two drugs under evaluation in human clinical trials for the treatment of certain cancers. Another anticancer compound is expected to move into Phase II clinical trials later this year. Beyond that, Agouron scientists are engaged in a dozen diverse programs, developing drugs to treat everything from ophthalmic disease to the common cold. Worried about security? Please read this. If you're not using Microsoft Internet Explorer, you're not seeing all that Microsoft Investor has to offer. Terms of Use and Privacy Policy. cÿ1998 Microsoft Corporation and/or its suppliers. All rights reserved. c 1998 Business Wire.